ReNeuron encouraged by 12-month data from cell therapy for degenerative eye disease
The update was provided alongside news the group had applied to the US regulator to add a further nine people to its phase I/IIa clinical study
Sector
Health
1090 stories · page 51 of 55
Matinas BioPharma to start Part 2 study of MAT2203 to treat HIV patients with cryptococcal meningitis
The announcement comes after data from Part 1 demonstrated that MAT2203 was safe and well-tolerated
Compumedics secures US Food and Drug Administration approval for Orion Lifespan™ technology
The company is focused on the commercialisation of its technology in the US and advancing regulatory submissions in other territories.
Antisense Therapeutics eyes wider potential for ATL1102 after positive phase II DMD trial results
The company is developing and commercialising antisense pharmaceuticals for large unmet markets. Antisense therapy is a form of treatment for genetic disorders or infections.
Dyadic CEO touts how firm’s technology may speed coronavirus vaccine creation on Fox Business
CEO Mark Emalfarb said the company applies its proprietary C1 gene expression platform to speed up the development of vaccines, drugs
THC Global is all licensed up and ready to go: MST Access
THC has the potential to cultivate cannabis in over 100,000 square metres of hydroponic greenhouse facilities in Australia at its Bundy, Eden Farms and Ballina sites.
Nabis Holdings set to expand product offerings in Arizona after securing state hemp license
The license gives Nabis the ability to manufacture its own CBD oil extracts for its BIS and BIS+ line of products
Opyl to use artificial intelligence to digitally transform Australia’s healthcare sector
Combining new technologies and healthcare expertise, the company’s key offerings include optimising clinical study design and recruitment strategies to better understand the patient experience.
Genprex reports positive preclinical data on treating resistant metastatic lung cancers
The data concerns the TUSC2 tumor suppressor gene, which is an active agent in Genprex’s Oncoprex immunogene therapy
Medlab Clinical ahead of expectations with Phase 2 Depression Trial for NRGBiotic™
Study timelines are progressing as planned and at this point the trial should complete ahead of expectations.
Hill Street Beverage strikes deal with Peak Processing Solutions for cannabis infused drinks
Peak Processing is a Canadian cannabis co-packing and white label product manufacturing firm
Namaste Technologies to lend C$300,000 to chocolate maker Choklat to maximise opportunity for edibles
Namaste currently holds a 49% interest in Choklat and revealed it had now struck a secured convertible loan deal
IPO Roundup: Viela Bio leads batch of biotechs, but others pull back at the 11th hour
A few biotechs and a banking company went public Thursday morning, but not everyone made it to the finish line
MMJ Group set to reap rewards from cannabis investments
The company’s chairman Peter Wall said the 2019 financial year was a significant year of transformation for MMJ in his letter to shareholders in the annual report.
Cello Health expands further into US with US$10.5mln acquisition of ISS
ISS helps healthcare and pharma companies meeting with US regulators to discuss the next steps for their new drug or medical device
Medlab Clinical obtains positive data proving efficacy of NanaBidial medicinal cannabis in completed phase-one trial
The clinical study was a blinded, randomised trial showing plasma concentrations were achieved quickly with a product half-life of about four hours.
Tissue Regenix adds manufacturing capacity in US expansion push
“Having commenced a second shift at the beginning of the year in our current facility in San Antonio, the phased build out of this new facility will allow us to meet the growing requirements of our customers well into the future," said boss
Noble Research repeats Outperform rating and $9 target on Dyadic following second quarter results
Recent developments "provide not only more visibility for the company, but also validity for the technology and help expand shareholder base."
CytoDyn reports positive results from dose escalating trial with lead drug leronlimab as a HIV monotherapy
The viral load suppression rate after 10 weeks was 68%, 94% and 85% respectively for patients on a 350 mg, 525 mg, and 700 mg drug dose regimen
BevCanna's powdered cannabis expected to pass California regulations following strong independent tests
The water-soluble powder was shown to deliver target concentrations of THC, which provides consumers with confidence that they’re getting the correct dose